CHIOME BIOSCIENCE INC. Supplement Documents for Financial Results Q3 FY12/21
Nov. 12, 2021
To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs
Chiome Bioscience Inc.
Agenda
１．Overview of Q3 FY12/21 "Financial results"
２．Overview of Q3 FY12/21 "Operation highlights"
Appendix.
Corporate information
Pipeline information
2 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Overview of
Q3 FY12/21 "Financial results"
Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.
3 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Profit and Loss
(JPY in millions)
Q3 FY2020 | Q3 FY2021 | Increase | ||
(decrease) | ||||
Net sales | 312 | 541 | 229 | |
Drug Discovery & | 2 | 103 | 100 | • Upfront payment of the License |
Agreement with Shanghai Henlius | ||||
Development | ||||
Biotech, Inc. for LIV-2008/2008b | ||||
Drug Discovery | 309 | 438 | 128 | • Growth in business with domestic |
Support | pharmaceutical companies | |||
COS/SGA | 1,392 | 1,392 | 0 | |
R&D Expense | 951 | 860 | (90) | • Cost of the study drug manufacturing |
in CBA-1535 program | ||||
Other costs | 441 | 532 | 90 | • Up in material costs due to increased |
business transactions | ||||
Operating Loss | (1,080) | (850) | 229 | |
Ordinary Loss | (1,087) | (843) | 244 | |
Net Loss | (1,087) | (842) | 245 | |
4 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Balance Sheet
(JPY in millions) | |||
As of | Dec. 31, | As of Sep. 30, | |
2020 | 2021 | ||
Current assets | 3,248 | 2,675 | |
（Cash on hand in banks) | 2,686 | 2,071 | |
(Other current assets) | 562 | 604 | |
Non-current assets | 246 | 274 | |
Total assets | 3,494 | 2,950 | |
Current Liabilities | 342 | 468 | |
Non-current liabilities | 41 | 53 | |
Total liabilities | 384 | 522 | |
Total net assets | 3,109 | 2,428 | |
Total liabilities and net assets | 3,494 | 2,950 | |
5 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Chiome Bioscience Inc. published this content on 12 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2021 07:26:09 UTC.
